Today Biogen
Idec BIIB announced the company recently submitted a
Biologics License Application (BLA) to the U.S. Food and Drug
Administration (FDA) for the marketing approval of recombinant factor IX
Fc fusion protein (rFIXFc) for the treatment of hemophilia B. rFIXFc is
the first product candidate in a new class of long-lasting clotting
factor therapies that are being developed with the goals of reducing the
burden of treatment for this condition and enhancing protection from
bleeding. The regulatory submission was based on results from B-LONG,
the largest registrational phase 3 clinical study in hemophilia B to
date.
“The submission to FDA of rFIXFc is an important milestone towards the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in